Bispecific Antibodies in the Treatment of Multiple Myeloma: Expert and Patient Perspectives : Episode 3
Patient Experience With Treatment for Multiple Myeloma and Clinical Trial Participation
Anne-Marie Jacob describes her early treatment regimen for multiple myeloma and her experience with clinical trial enrollment.
EP: 1.A Patient’s Experience With a Multiple Myeloma Diagnosis
EP: 2.Resources for Patient Education
Now Viewing
EP: 3.Patient Experience With Treatment for Multiple Myeloma and Clinical Trial Participation
EP: 4.The Role of Teclistamab in Multiple Myeloma
EP: 5.Process of Administering Teclistamab and Other Bispecific Agents
EP: 6.Step-Up Doses in Patients Receiving Teclistamab for Multiple Myeloma
EP: 7.Discussing Consent for Supportive Care Agents with Patients with Multiple Myeloma
EP: 8.Advice to Patients with Multiple Myeloma Facing Hospital Admission For Teclistamab Therapy
EP: 9.Counseling Patients Receiving Teclistamab for Multiple Myeloma on COVID Precautions
EP: 10.Counseling Patients with Multiple Myeloma on the Infection Risks of BCMA-Targeting Bispecifics
EP: 11.CAR T-Cell Therapy in Multiple Myeloma and Quality of Life
EP: 12.Advice for Patients, Nurse Practitioners, and Community Oncologists on Teclistamab Therapy in Multiple Myeloma
EP: 13.Recap: Teclistamab in Multiple Myeloma: A Patient’s Journey
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
